663 related articles for article (PubMed ID: 28647837)
21. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
22. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
23. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.
Song HY; Biancucci M; Kang HJ; O'Callaghan C; Park SH; Principe DR; Jiang H; Yan Y; Satchell KF; Raparia K; Gius D; Vassilopoulos A
Oncotarget; 2016 Dec; 7(49):80336-80349. PubMed ID: 27637077
[TBL] [Abstract][Full Text] [Related]
24. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
25. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
26. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
27. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
29. KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.
Ischenko I; Zhi J; Hayman MJ; Petrenko O
Oncotarget; 2017 Mar; 8(11):17995-18009. PubMed ID: 28152508
[TBL] [Abstract][Full Text] [Related]
30. KRAS: feeding pancreatic cancer proliferation.
Bryant KL; Mancias JD; Kimmelman AC; Der CJ
Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
[TBL] [Abstract][Full Text] [Related]
31. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
[TBL] [Abstract][Full Text] [Related]
32. Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS.
Wang D; Bi Y; Hu L; Luo Y; Ji J; Mao AZ; Logsdon CD; Li E; Abbruzzese JL; Li Z; Yang VW; Lu W
Cell Commun Signal; 2019 Feb; 17(1):19. PubMed ID: 30819189
[TBL] [Abstract][Full Text] [Related]
33. DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells.
Hu M; Zhao Y; Cao Y; Tang Q; Feng Z; Ni J; Zhou X
Cancer Sci; 2020 Oct; 111(10):3588-3599. PubMed ID: 32767829
[TBL] [Abstract][Full Text] [Related]
34. Ablation of insulin receptor substrates 1 and 2 suppresses
Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
[TBL] [Abstract][Full Text] [Related]
35. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
37. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
Moss DY; McCann C; Kerr EM
Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
[TBL] [Abstract][Full Text] [Related]
38. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.
Ruiz CF; Montal ED; Haley JA; Bott AJ; Haley JD
FASEB J; 2020 Aug; 34(8):10574-10589. PubMed ID: 32568455
[TBL] [Abstract][Full Text] [Related]
39. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
40. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.
Wang M; Han J; Marcar L; Black J; Liu Q; Li X; Nagulapalli K; Sequist LV; Mak RH; Benes CH; Hong TS; Gurtner K; Krause M; Baumann M; Kang JX; Whetstine JR; Willers H
Cancer Res; 2017 Apr; 77(8):2018-2028. PubMed ID: 28202526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
